List of life sciences

Arpeggio Biosciences Raises $17 Million in Series A Funding Led by Builders VC

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Machine learning, Asos, CEO, Technology, Agriculture, Disease, Factor X, MD, Database, Khosla Ventures, Therapy, Builder, Algorithm, List of life sciences, General partnership, Â, Pharmaceutical industry, Medical imaging, Arpeggio, Tencent

Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020.

Key Points: 
  • Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020.
  • Funding was led by Builders VC and will support ongoing development of Arpeggios drug pipeline as well as its transcription-monitoring technologies.
  • This Series A funding will enable us to continue our mission of discovering new therapies for diseases arising through dysregulation of transcription, said Joey Azofeifa, Ph.D., Founder and CEO, Arpeggio.
  • Using machine learning, Arpeggio reconstructs the biological networks affected by the molecule and matches the molecule to diseases where the compound could be therapeutically relevant.

Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster

Retrieved on: 
Wednesday, September 7, 2022
The Retreat, Technology, Safety, Risk, Medtech, Board of directors, Health, Hub, U.S. Securities and Exchange Commission, Genolier Swiss Medical Network SA, Electron capture, Twitter, Academy of Clinical Laboratory Physicians and Scientists, Delegate, Patient, Philosophy, Time, Board, SEC, SIX Swiss Exchange, Industry, Cyberknife, Security (finance), NASDAQ, Ageing, R, Radiation, Lists of diseases, LinkedIn, Investment, Hospital, Faculty, Scientist, Clinique, Neoplasm, Private Securities Litigation Reform Act, YouTube, SWX, Heart, Education, Pharma, Paola Lattus, List of life sciences, Annual report, Ohio bioscience sector, Forward-looking statement, Pharmaceutical industry, Medical imaging, Facebook, Physician

SUNNYVALE, Calif., Sept. 7, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care. Genolier Innovation Hub will unite companies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster. The Hub is expected to open in early 2024.

Key Points: 
  • Genolier Innovation Hub will unitecompanies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster.
  • Genolier Innovation Hub will be located in the heart of the Genolier Healthcare Campus in Genolier, Switzerland.
  • "We are proud to lead the radiation therapy industry as an anchor for Genolier Innovation Hub.
  • "We look forward to partnering with Genolier Innovation Hub to usher in a new level of collaboration that speeds the progress made in patient-centric care.

Clarivate to Present at Upcoming Investor Conferences in September 2022

Retrieved on: 
Wednesday, September 7, 2022
Professional services, Health care, NYSE, Technology, View, Academy, Solution, Final good, Multimedia, List of life sciences, Conference, Invention, Clarivate, Management, Video game

LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the following investor conferences in September 2022.

Key Points: 
  • LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the following investor conferences in September 2022.
  • Barclays Global Financial Services Conference on Monday, September 12, 2022 at 9:00 am Eastern Time.
  • Goldman Sachs Communacopia + Technology Conference on Thursday, September 15, 2022 at 11:30 am Pacific Time (2:30 pm Eastern Time) at https://event.webcasts.com/starthere.jsp?ei=1569224&tp_key=0b52f79e6f&tp... and will be available for replay.
  • Clarivate is a global leader in providing solutions to accelerate the pace of innovation.

Clarivate to Present at Upcoming Investor Conferences in September 2022

Retrieved on: 
Wednesday, September 7, 2022
Professional services, Health care, NYSE, Technology, Academy, Solution, Final good, List of life sciences, Conference, Invention, Clarivate, Management

LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the following investor conferences in September 2022.

Key Points: 
  • LONDON, Sept. 7, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear, Chief Executive Officer, and Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the following investor conferences in September 2022.
  • Barclays Global Financial Services Conference on Monday, September 12, 2022 at 9:00 am Eastern Time.
  • Goldman Sachs Communacopia + Technology Conference on Thursday, September 15, 2022 at 11:30 am Pacific Time (2:30 pm Eastern Time) at https://event.webcasts.com/starthere.jsp?ei=1569224&tp_key=0b52f79e6f&tp... and will be available for replay.
  • Clarivate is a global leader in providing solutions to accelerate the pace of innovation.

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

Retrieved on: 
Wednesday, September 7, 2022
FW, CEO, Research, Stomach, Cystic Fibrosis Foundation, Niclosamide, Nutrient, Steatorrhea, Fats, Clostridial necrotizing enteritis, U.S. Securities and Exchange Commission, CDMO, GMP, BOCA, GLOBE, Company, Patient, CP, Exocrine pancreatic insufficiency, CTM, Yarrowia, Hope, First wave, CMC, Cystic fibrosis, List of life sciences, EPI, FDA, Weight loss, Ulcerative colitis, Capsule, Trial of the century, Investigational New Drug, Security (finance), Food, Diarrhea, NASDAQ, AAPS, GI, Duodenum, PERT, Acquisition, CF, IND, CFA, Technology company, Clinical trial, Digestion, Pharmaceutical industry

BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI). First Wave BioPharma now plans to submit an Investigational New Drug (IND) amendment to the U.S. Food & Drug Administration (FDA) for a Phase 2 “proof-of-concept” clinical study investigating the optimized version of adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.

Key Points: 
  • BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI).
  • First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.
  • The selection of the enteric microgranule drug delivery technology follows extensive research by First Wave BioPharma and our drug delivery formulation partner, Pace Life Sciences, into the development and manufacturing of the optimized adrulipase formulation, said James Sapirstein, President and CEO of First Wave BioPharma.
  • Additionally, First Wave BioPharma previously published a white paper detailing the development of the microgranule formulation for adrulipase.

Head of Global Healthcare Logistics Company CRYOPDP Wins Business Worldwide Magazine CEO Award

Retrieved on: 
Wednesday, September 7, 2022
Health care, DTP, COVID-19, Legislation, Richard Barker (life sciences and healthcare leader), Vaccine, Mecum Dealmakers, Code of Federal Regulations, Heart, Intelligence, Hospital, Personal injury lawyer, List of life sciences, Patient, Movement, Therapy, News, Failure, Name, Chief executive officer, Health, Management, Pharmaceutical industry

Unlike many other business awards, which focus on companies as a whole, here the emphasis is on the people who lead them.

Key Points: 
  • Unlike many other business awards, which focus on companies as a whole, here the emphasis is on the people who lead them.
  • Cedric Picaud was the outright winner in his category, being named 'Most Innovative CEO in the Healthcare Logistics Industry'.
  • CRYOPDP is a global expert in temperature-controlled logistics and supply chain solutions for clients in the Life Science and Healthcare field.
  • To find out more about CRYOPDP's trailblazing work, visit https://www.cryopdp.com/
    Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world.

Head of Global Healthcare Logistics Company CRYOPDP Wins Business Worldwide Magazine CEO Award

Retrieved on: 
Wednesday, September 7, 2022
Health care, DTP, COVID-19, Legislation, Richard Barker (life sciences and healthcare leader), Vaccine, Mecum Dealmakers, Code of Federal Regulations, Heart, Intelligence, Hospital, Personal injury lawyer, List of life sciences, Patient, Movement, Therapy, News, Failure, Name, Chief executive officer, Health, Management, Pharmaceutical industry

Unlike many other business awards, which focus on companies as a whole, here the emphasis is on the people who lead them.

Key Points: 
  • Unlike many other business awards, which focus on companies as a whole, here the emphasis is on the people who lead them.
  • Cedric Picaud was the outright winner in his category, being named 'Most Innovative CEO in the Healthcare Logistics Industry'.
  • CRYOPDP is a global expert in temperature-controlled logistics and supply chain solutions for clients in the Life Science and Healthcare field.
  • To find out more about CRYOPDP's trailblazing work, visit https://www.cryopdp.com/
    Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world.

Hitachi Acquires Key Industry 4.0 Systems Integrator -- Flexware Innovation

Retrieved on: 
Wednesday, September 7, 2022
Cloud, Transfer, CEO, Technology, Safety, Digital technology, Culture, Acquisition, NEW, Health Industry Business Communications Council, Automation, Metal, TSE, Engineering, Lonelyland, Information technology, Harman Becker Automotive Systems, Food, SI, List of life sciences, Operational technology, TOTAL, Industry, MES, Steel, Enterprise resource planning, Partnership, Mobility, Whitlock, Solution, Business intelligence, Digital Systems, Manufacturing execution system, News, Growth, ERP, BI, Public utility, Systems integrator, Automotive industry, Foodservice, Supervisory control, Retail, Online shopping, Electric power industry, Management, Sullair, OT, SCADA

NEW YORK and TOKYO, Sept 7, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) today announced that on August 31, 2022 it acquired Flexware Innovation, Inc. which has been a leading manufacturing Systems Integrator (SI) since 1996.

Key Points: 
  • NEW YORK and TOKYO, Sept 7, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) today announced that on August 31, 2022 it acquired Flexware Innovation, Inc. which has been a leading manufacturing Systems Integrator (SI) since 1996.
  • Further, Hitachi formed Hitachi Industrial Holdings Americas(4) in 2020 to strengthen integrated business operations of industry field in the region.
  • Under the Hitachi Industrial Holdings Americas leadership are Sullair, JR Automation, and Flexware Innovation, the newly acquired company.
  • Whitlock will remain as President & CEO of Flexware Innovation in partnership with the leaders of Hitachi Industrial Holdings Americas.

atai Life Sciences to Participate in September Investor Events

Retrieved on: 
Tuesday, September 6, 2022
Anxiety, Mental health, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Therapy, Depression, List of life sciences, Annual report, Private Securities Litigation Reform Act, Addiction, Patient, SEC, Pharmaceutical industry

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Key Points: 
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
  • atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.
  • Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements.
  • atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

hC Bioscience Expands Leadership and Research & Development Teams

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Massachusetts General Hospital, DMPK, Metabolomics, Patient, National Center for Advancing Translational Sciences, University, Cancer, Computer science, Biological engineering, Research, RNA transfection, Therapy, Â, Precision medicine, PTC Therapeutics, Mutation, CyTOF, Mechanical, HC, Savitribai Phule Pune University, Faculty, Broad Institute, Georgia Tech, B cell, Lists of diseases, Disease, GLOBE, Alnylam Pharmaceuticals, Hospital, Leadership, IP, MS, Weizmann Institute of Science, Drug discovery, Software, List of life sciences, Mechanical engineering, Proteomics, Virology, Management, Pharmaceutical industry, Technology, DRS

Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as chief technology officer.

Key Points: 
  • Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as chief technology officer.
  • Under their leadership, we continue to add members to our R&D team with expertise in tRNA biology, computational and formulation.
  • Prior to joining hC Bioscience, Dr. Landesman served as senior vice president of research and translational medicine at Karyopharm Therapeutics.
  • hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction.